BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30847823)

  • 41. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
    Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Baseline
    Aide N; Fruchart C; Nganoa C; Gac AC; Lasnon C
    Eur Radiol; 2020 Aug; 30(8):4623-4632. PubMed ID: 32248365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients.
    Zschaeck S; Li Y; Lin Q; Beck M; Amthauer H; Bauersachs L; Hajiyianni M; Rogasch J; Ehrhardt VH; Kalinauskaite G; Weingärtner J; Hartmann V; van den Hoff J; Budach V; Stromberger C; Hofheinz F
    PLoS One; 2020; 15(7):e0236841. PubMed ID: 32730364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma.
    Mayerhoefer ME; Riedl CC; Kumar A; Gibbs P; Weber M; Tal I; Schilksy J; Schöder H
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2760-2769. PubMed ID: 31286200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Value of baseline and end of chemotherapy
    Xiao Z; Mo Y; Long W; Li R; Li X; Wei Y; Fan W; Zhang X
    Leuk Lymphoma; 2021 Dec; 62(12):2873-2881. PubMed ID: 34165390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
    Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients.
    Mayerhoefer ME; Giraudo C; Senn D; Hartenbach M; Weber M; Rausch I; Kiesewetter B; Herold CJ; Hacker M; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Feb; 41(2):101-5. PubMed ID: 26402137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
    Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
    Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
    Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.
    Ceriani L; Martelli M; Zinzani PL; Ferreri AJ; Botto B; Stelitano C; Gotti M; Cabras MG; Rigacci L; Gargantini L; Merli F; Pinotti G; Mannina D; Luminari S; Stathis A; Russo E; Cavalli F; Giovanella L; Johnson PW; Zucca E
    Blood; 2015 Aug; 126(8):950-6. PubMed ID: 26089397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.
    Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W
    Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic bulk volume predicts survival in a homogeneous cohort of stage II/III diffuse large B-cell lymphoma patients undergoing R-CHOP treatment.
    Jin H; Jin M; Lim CH; Choi JY; Kim SJ; Lee KH
    Front Oncol; 2023; 13():1186311. PubMed ID: 37384292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic Tumor Burden Assessed by Dual Time Point [
    Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
    Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Prognostic Value of
    Shao D; Gao Q; Cheng Y; Du DY; Wang SY; Wang SX
    Korean J Radiol; 2021 Mar; 22(3):425-434. PubMed ID: 33236543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.